IP10 and IL-8 play an important role in tumor promotion and inhibition, combining these two factors as biomarkers has more clinical significance, and an increased IP10/IL-8 (S2/S0) ratio indicates that patients can benefit more from the treatment. Here, CXCL8 is linked to neoplasm.